Sign inJoin waitlistJoin the waitlist

Yazan Madanat

Associate Professor of Internal Medicine · UT Southwestern Medical Center

Credentials: · · ·

History

UT Southwestern Medical Center
Present

Cleveland Clinic Foundation
2016–2019
Cleveland Clinic Foundation
2013–2016
King Hussein Cancer Center
2012–2013
Al-Hussein Hospital, Jordan
2011–2012
University of Jordan Faculty of Medicine, Jordan
2005–2011

Research

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
Blood Advances · 2022 · 182 citations
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised,…
The Lancet · 2024 · 125 citations
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 120 citations

Amer Zeidan
22 papers
Robert Collins
19 papers
Stephen Chung
19 papers
Mikkael Sekeres
18 papers
Uma Borate
17 papers
Michael Savona
15 papers
Olga Weinberg
15 papers
Alice Mims
14 papers
Joshua Zeidner
14 papers
RK
Rami Komrokji
14 papers
FH
Fieke Hoff
13 papers · 9 as a resident
PP
Prapti Patel
13 papers

Clinical trials

Luspatercept + Darbepoetin in MDS
Site PI · Recruiting · Phase 2
Yale University
2025–2030
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
Site PI · Recruiting · Phase 2
Uma Borate
2023–2028
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Site PI · Recruiting · Phase 2
Alice Mims
2022–2029
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Site PI · Recruiting · Phase 1
OHSU Knight Cancer Institute
2021–2026